ReviewAntibiotics (Basel, Switzerland)2023
The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients.
Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 24 citations in OpenAlex.
- Rethinking Cefepime Neurotoxicity: An Integrated PK-Neuromonitoring Approach for Neurocritical Care.Neurocritical care · 2026Article
- From Intelligent Operating Room to Smart ICU: Digital Continuity, AI-Supported Decision-Making and CRRT as a Model of Pharmacokinetic Personalization in Critical Care.Healthcare (Basel, Switzerland) · 2026Review
- Model Ensembling and Machine Learning Approaches to Predict the First Dose of Amoxicillin in Intensive Care.CPT: pharmacometrics & systems pharmacology · 2026Article
- Urine NGAL adds to serum creatinine in predicting cefepime clearance in critically ill children at high risk of acute kidney injury.International journal of antimicrobial agents · 2026Article
- Extended vs Intermittent Infusion of Meropenem with Colistimethate Sodium and Risk of Acute Kidney Injury in Critically Ill Patients: A Propensity Score-Matched Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?Chemotherapy · 2026Review
- Relationship between antibiotic use and short-term risk of mortality in patients with sepsis-associated encephalopathy: a study based on the medical information mart for intensive care database.BMC infectious diseases · 2025Observational
- Development of a UHPLC-UV/Vis Method for Simultaneously Determining Six Beta-Lactam Antibiotics in Plasma: A Tool for the Clinical Implementation of Therapeutic Monitoring of Beta-Lactams.Antibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Dosing During Continuous Venovenous Hemodiafiltration in Septic Shock Patients: A Prospective, Multicenter Study Protocol.Antibiotics (Basel, Switzerland) · 2025Article
- Unraveling Ceftriaxone Dosing: Free Drug Prediction, Threshold Optimization, and Model Validation.The AAPS journal · 2025Article
- Economic impact of individualized antimicrobial dose optimization in the critically ill patient in Spain.Frontiers in pharmacology · 2025Article
- Microbial diversity and composition in the gut microbiome of patients during systemic inflammatory response syndrome: can we use gut bacteria as potential biomarkers to characterize sepsis?Frontiers in cellular and infection microbiology · 2025Article
- Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptibleAntimicrobial agents and chemotherapy · 2024Article
- Monte Carlo simulations of cefepime in children receiving continuous kidney replacement therapy support continuous infusions for target attainment.Journal of intensive care · 2024Article
- Prevalence of the Cefazolin Inoculum Effect (CzIE) in Nasal Colonizing Methicillin-SusceptiblemedRxiv : the preprint server for health sciences · 2024Article
- Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review.Journal of intensive medicine · 2024Review
- The Subcutaneous Administration of Beta-Lactams: A Case Report and Literary Review-To Do Small Things in a Great Way.Infectious disease reports · 2024Review
- Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.Critical care (London, England) · 2023Review
- Assessing the Potential of Gallic Acid and Methyl Gallate to Enhance the Efficacy of β-Lactam Antibiotics against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Multidrug Resistance: Clinical Implications for Infection Management in Critically Ill Patients.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta-lactams (BL) are the first line agents for the antibiotic management of critically ill patients with sepsis or septic shock. BL are hydrophilic antibiotics particularly subject to unpredictable concentrations in the context of critical illness because of pharmacokinetic (PK) and pharmacodynamics (PD) alterations. Thus, during the last decade, the literature focusing on the interest of BL therapeutic drug monitoring (TDM) in the intensive care unit (ICU) setting has been exponential. Moreover, recent guidelines strongly encourage to optimize BL therapy using a PK/PD approach with TDM. Unfortunately, several barriers exist regarding TDM access and interpretation. Consequently, adherence to routine TDM in ICU remains quite low. Lastly, recent clinical studies failed to demonstrate any improvement in mortality with the use of TDM in ICU patients. This review will first aim at explaining the value and complexity of the TDM process when translating it to critically ill patient bedside management, interpretating the results of clinical studies and discussion of the points which need to be addressed before conducting further TDM studies on clinical outcomes. In a second time, this review will focus on the future aspects of TDM integrating toxicodynamics, model informed precision dosing (MIPD) and "at risk" ICU populations that deserve further investigations to demonstrate positive clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.